SIAGOSIDE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C73H129N3O30
Molecular Weight	1528.8075
Optical Activity	UNSPECIFIED
Defined Stereocenters	28 / 28
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[H][C@]1(O[C@@]2(C[C@H](O)[C@H]1NC(C)=O)O[C@H]3[C@@H](O[C@@H]4O[C@H](CO)[C@H](O)[C@H](O[C@@H]5O[C@H](CO)[C@H](O)[C@H](O)[C@H]5O)[C@H]4NC(C)=O)[C@@H](CO)O[C@@H](O[C@@H]6[C@@H](CO)O[C@@H](OC[C@H](NC(=O)CCCCCCCCCCCCCCCCC)[C@H](O)\C=C\CCCCCCCCCCCCC)[C@H](O)[C@H]6O)[C@@H]3OC2=O)[C@H](O)[C@H](O)CO

InChI

InChIKey=WVHBJHLTCHODOA-MYYVOHNDSA-N

InChI=1S/C73H129N3O30/c1-5-7-9-11-13-15-17-19-20-22-24-26-28-30-32-34-52(87)76-44(45(84)33-31-29-27-25-23-21-18-16-14-12-10-8-6-2)41-96-69-61(94)59(92)62(50(39-80)99-69)101-71-67-66(106-73(72(95)104-67)35-46(85)53(74-42(3)82)65(105-73)55(88)47(86)36-77)63(51(40-81)100-71)102-68-54(75-43(4)83)64(57(90)49(38-79)97-68)103-70-60(93)58(91)56(89)48(37-78)98-70/h31,33,44-51,53-71,77-81,84-86,88-94H,5-30,32,34-41H2,1-4H3,(H,74,82)(H,75,83)(H,76,87)/b33-31+/t44-,45+,46-,47+,48+,49+,50+,51+,53+,54+,55+,56-,57-,58-,59+,60+,61+,62+,63-,64+,65+,66-,67+,68-,69+,70-,71-,73-/m0/s1

HIDE SMILES / InChI

Description
Sources: http://drugprofiles.informa.com/drug_profiles/2241-sygen | https://www.ncbi.nlm.nih.gov/pubmed/11805614 | https://www.ncbi.nlm.nih.gov/pubmed/3027926

Siagoside (Sygen, AGF 2) is a naturally occurring substance in the nerve cell’s membrane that is thought to play a role in cell growth, development, and repair. Siagoside completed phase 2 trials for parkinson's disease (PD) treatment. Sygen appears to be beneficial in patients with severe spinal cord injury. Treatment results in a 52% decrease in mortality 48 hours after the induction of ischemia in gerbils by permanent unilateral ligation of the common carotid artery.

CNS Activity

Originator

Approval Year

PubMed

Title	Date	PubMed
Ganglioside AGF2 prevents the cognitive impairments and cholinergic cell loss following intraventricular colchicine.	1991 Jun	2029933
Time course of the translocation and inhibition of protein kinase C during complete cerebral ischemia in the rat.	1993 Oct	8376989
The Sygen multicenter acute spinal cord injury study.	2001 Dec 15	11805614

Sample Use Guides

In Vivo Use Guide

Monkeys: Siagoside (30 mg/kg) was administered intravenously immediately after initiation of recirculation and intramuscularly twice a day for 48 hours.

Route of Administration: Intravenous

Name

Type

Language

SIAGOSIDE

Official Name

English

siagoside [INN]

Common Name

English

GANGLIOSIDE GM1 LACTONE

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C107389